Current treatment options in RAS mutant metastatic colorectal cancer patients: a meta-analysis of 14 randomized phase III trials

PURPOSE: Although biomarkers for patients with metastatic colorectal cancer exist, the benefit patients with RAS mutated tumors derive from established regimens is unclear. METHODS: Efficacy of therapeutic strategies available for RAS mutated patients (addition of chemotherapeutic agents and/or anti...

Descripción completa

Detalles Bibliográficos
Autores principales: Stahler, Arndt, Heinemann, Volker, Ricard, Ingrid, von Einem, Jobst C., Giessen-Jung, Clemens, Westphalen, Christoph Benedikt, Michl, Marlies, Heinrich, Kathrin, Miller-Phillips, Lisa, Jelas, Ivan, Stintzing, Sebastian, Modest, Dominik Paul
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2020
Materias:
Review – Clinical Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7324435/
https://www.ncbi.nlm.nih.gov/pubmed/32561975
http://dx.doi.org/10.1007/s00432-020-03290-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7324435/
https://www.ncbi.nlm.nih.gov/pubmed/32561975
http://dx.doi.org/10.1007/s00432-020-03290-y

Ejemplares similares